Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation
January 08 2018 - 2:29PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of NewLink Genetics
Corporation (“NewLink” or the “Company”) (NASDAQ:NLNK) into
potential breaches of fiduciary duty by the Company’s Board of
Directors (the “Board”).
NewLink, headquartered in Ames, Iowa, is a biopharmaceutical
company. Despite the Company’s low market capitalization and
increasing investment in research and development since it became a
public company in 2011, the Board continues to make decisions,
without shareholder approval, that significantly diminish
shareholder value and do not benefit the Company. Based on this, it
appears the Board lacks the ability to fairly assess and oversee
the Company’s direction and leadership.
Current NewLink stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Ryan Jerome (rjerome@nfllp.com) to
discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180108006722/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024